Literature DB >> 23421925

Cystoid macular edema secondary to nanoparticle albumin-bound Paclitaxel therapy.

Ehsan Rahimy1, David Sarraf.   

Abstract

The authors report a case of nanoparticle albumin-bound paclitaxel-induced cystoid macular edema (CME) without fluorescein angiographic leakage in a patient being treated for metastatic breast cancer. The CME briskly improved 3 weeks after the chemotherapeutic agent was discontinued and was completely resolved after 6 weeks. Patients receiving taxane therapy must be counseled to report any vision problems during their treatment period because early recognition of this rare but severe adverse event can facilitate appropriate intervention to reverse visual compromise and minimize any potential long-term ophthalmologic sequelae. Copyright 2013, SLACK Incorporated.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23421925     DOI: 10.3928/23258160-20130212-02

Source DB:  PubMed          Journal:  Ophthalmic Surg Lasers Imaging Retina        ISSN: 2325-8160            Impact factor:   1.300


  3 in total

1.  Cystoid macular edema associated with chemotherapy.

Authors:  Rajesh C Rao; Netan Choudhry
Journal:  CMAJ       Date:  2015-08-04       Impact factor: 8.262

2.  Intravitreal Ranibizumab Had Limited Effect on Cystoid Macular Edema Due to Albumin-Bound Paclitaxel: A Case Report and Literature Review.

Authors:  Suna Ye; Qiqi Fang; Jinyu Yao; Jianqiang Xing; Shibo Tang; Jacey Hongjie Ma
Journal:  Front Oncol       Date:  2021-12-13       Impact factor: 6.244

3.  Sub-Tenon Injections of Triamcinolone Acetonide Had Limited Effect on Cystoid Macular Edema Secondary to Nanoparticle Albumin-Bound-Paclitaxel (Abraxane).

Authors:  Naoki Matsuoka; Hiruma Hasebe; Tetsuji Mayama; Takeo Fukuchi
Journal:  Case Rep Ophthalmol Med       Date:  2015-08-23
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.